A single-arm exploratory study for the efficacy and safety of acupuncture in patients with taxane-induced peripheral neurotoxicity

A single-arm exploratory study for the efficacy and safety of acupuncture in patients with taxane-induced peripheral neurotoxicity - ACT-1 study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000048478

Enrollment

Registered

2022-08-01

Start date

2022-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

taxane-induced peripheral neurotoxicity

Interventions

Acupuncture

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patient with breast cancer who had received curative treatment more than 3 months ago 2) Received taxane. 3) Have "mild" or severer symptom in PRO-CTCAE item 39b 4) 18 years or older 5) ECOG PS 0 or 1

Exclusion criteria

Exclusion criteria: 1)Patient with peripheral neuropathy by other than taxane 2)have distant metastases or local recurrence 3)have fibromyalgia, inflammatory joint disease, or phantom limb pain 4)undergoing chemotherapy 5)have mental illness 6)have severe comorbidities 7)being pregnant or breastfeeding 8)history of acupuncture for CIPN

Design outcomes

Primary

Measure	Time frame
Change in average pain intensity between baseline and week 16.	—

Countries

Japan

Contacts

Public ContactHiroto Ishiki

National Cancer Center Hospital Department of Palliative Medicine

hishiki@ncc.go.jp0335422511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026